(11)C-methionine PET aids localization of microprolactinomas in patients with intolerance or resistance to dopamine agonist therapy
Bashari, W. A.
van der Meulen, M.
Powlson, A. S.
Brooke, A. M.
Scoffings, D. J.
O'Donovan, D. G.
Cheow, H. K.
Mendichovszky, I. A.
Kolias, A. G.
Rights© 2022. The Author(s).
MetadataShow full item record
PURPOSE: To assess the potential for (11)C-methionine PET (Met-PET) coregistered with volumetric magnetic resonance imaging (Met-PET/MR(CR)) to inform clinical decision making in patients with poorly visualized or occult microprolactinomas and dopamine agonist intolerance or resistance. PATIENTS AND METHODS: Thirteen patients with pituitary microprolactinomas, and who were intolerant (n = 11) or resistant (n = 2) to dopamine agonist therapy, were referred to our specialist pituitary centre for Met-PET/MR(CR) between 2016 and 2020. All patients had persistent hyperprolactinemia and were being considered for surgical intervention, but standard clinical MRI had shown either no visible adenoma or equivocal appearances. RESULTS: In all 13 patients Met-PET/MR(CR) demonstrated a single focus of avid tracer uptake. This was localized either to the right or left side of the sella in 12 subjects. In one patient, who had previously undergone surgery for a left-sided adenoma, recurrent tumor was unexpectedly identified in the left cavernous sinus. Five patients underwent endoscopic transsphenoidal selective adenomectomy, with subsequent complete remission of hyperprolactinaemia and normalization of other pituitary function; three patients are awaiting surgery. In the patient with inoperable cavernous sinus disease PET-guided stereotactic radiosurgery (SRS) was performed with subsequent near-normalization of serum prolactin. Two patients elected for a further trial of medical therapy, while two declined surgery or radiotherapy and chose to remain off medical treatment. CONCLUSIONS: In patients with dopamine agonist intolerance or resistance, and indeterminate pituitary MRI, molecular (functional) imaging with Met-PET/MR(CR) can allow precise localization of a microprolactinoma to facilitate selective surgical adenomectomy or SRS.
CitationPituitary. 2022 Aug;25(4):573-586. doi: 10.1007/s11102-022-01229-9. Epub 2022 May 24.
NoteRD&E staff can access the full-text of this article by clicking on the 'Additional Link' above and logging in with NHS OpenAthens if prompted.
Showing items related by title, author, creator and subject.
Management of malignant pleural effusion associated with trapped lung syndrome Qureshi, R. A.; Collinson, S. L.; Powell, R. J.; Froeschle, P. O.; Berrisford, R. G. (SAGE, 2008-04-03)Management of recurrent malignant pleural effusion associated with trapped lung syndrome remains problematic. An alternative treatment using a pleural catheter has been advocated. Between August 1999 and August 2002, 127 ...
Hockey: a pain in the butt! Isolated superior gluteal artery rupture following blunt pelvic trauma - an unusual case Burton, H.; Mossadegh, S.; McCarthy, R. (Royal College of Surgeons, 2021-03-01)Superior gluteal artery rupture is a rare complication of trauma but a significant one with potential for substantial morbidity and mortality. This case demonstrates the importance of early diagnosis and treatment of this ...
Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial Morgan, Robert D.; McNeish, Iain A.; Cook, Adrian D.; James, Elizabeth C.; Lord, Rosemary; Dark, Graham; Glasspool, Rosalind M.; Krell, Jonathan; Parkinson, Christine; Poole, Christopher J.; Hall, Marcia; Gallardo-Rincón, Dolores; Lockley, Michelle; Essapen, Sharadah; Summers, Jeff; Anand, Anjana; Zachariah, Abel; Williams, Sarah; Jones, Rachel; Scatchard, Kate; Walther, Axel; Kim, Jae-Weon; Sundar, Sudha; Jayson, Gordon C.; Ledermann, Jonathan A.; Clamp, Andrew R. (Elsevier, 2021-02-01)BACKGROUND: Platinum-based neoadjuvant chemotherapy followed by delayed primary surgery (DPS) is an established strategy for women with newly diagnosed, advanced-stage epithelial ovarian cancer. Although this therapeutic ...